The study examined the safety and efficacy of the drug vunakizumab in 70 elderly patients with moderate to severe plaque psoriasis, of whom 49 received vunakizumab and 21 received placebo.[1] The incidence of adverse events was similar in both groups—87.8% in the vunakizumab group versus 90.5% in the placebo group, with serious adverse events occurring in 10.2% of vunakizumab and 4.8% of placebo patients.[1] The most common adverse events in the vunakizumab group were increased blood glucose (22.4%), hypertriglyceridemia (12.2%), increased cholesterol (10.2%), eczema (10.2%), hyperuricemia (10.2%), and upper respiratory tract infection (10.2%).[1] Vunakizumab was more effective than placebo in improving psoriasis—at week 12, more patients in the vunakizumab group achieved PASI 75 (75 percent improvement) than placebo, and these results were maintained through week 52.[1] Patient-reported outcomes were better in the vunakizumab group than in the placebo group at 52 weeks.[1] The study concluded that vunakizumab is safe and effective in elderly patients with moderate to severe plaque psoriasis.[1]